论文信息 - Axitinib or bevacizumab (bev) plus FOLFOX or FOLFIRI as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC). - 字舞流文

Axitinib or bevacizumab (bev) plus FOLFOX or FOLFIRI as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC).

C. Tournigand | J. Bendell | A. Ricart | C. Barone | A. Sobrero | J. Tarazi | B. Rosbrook | M. Bednarczyk | A. Świeboda-Sadlej | I. Chung